Sutro Biopharma Dividends
| STRO Stock | USD 15.52 0.92 6.30% |
As of the 9th of February 2026, Dividends Paid is likely to drop to about 393.8 K. In addition to that, Dividend Paid And Capex Coverage Ratio is likely to grow to -67.55. Sutro Biopharma's past performance could be the main factor of why investors trade Sutro Biopharma stock today. Investors should clearly understand every aspect of the Sutro Biopharma dividend schedule, including its future sustainability, and how it might impact an overall investment strategy. This tool is helpful to digest Sutro Biopharma's dividend schedule and payout information. Sutro Biopharma dividends can also provide a clue to the current valuation of Sutro Biopharma.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | 532.5 K | 393.8 K | |
| Dividend Paid And Capex Coverage Ratio | (71.10) | (67.55) |
Investing in stocks that pay dividends is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in Sutro Biopharma must own a stock before its ex-dividend date to receive its next dividend.
Sutro Biopharma Dividends Paid Over Time
Today, most investors in Sutro Biopharma Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Sutro Biopharma's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's dividends paid growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Sutro Biopharma dividends paid as a starting point in their analysis.
The total amount of dividends that a company has paid out to its shareholders over a specific period. Dividends Paid |
| Timeline |
Will Biotechnology sector continue expanding? Could Sutro diversify its offerings? Factors like these will boost the valuation of Sutro Biopharma. If investors know Sutro will grow in the future, the company's valuation will be higher. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Sutro Biopharma data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (2.60) | Revenue Per Share | Quarterly Revenue Growth 0.138 | Return On Assets | Return On Equity |
Understanding Sutro Biopharma requires distinguishing between market price and book value, where the latter reflects Sutro's accounting equity. The concept of intrinsic value - what Sutro Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Sutro Biopharma's price substantially above or below its fundamental value.
Please note, there is a significant difference between Sutro Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sutro Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Sutro Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.